Suggested remit: To appraise the clinical and cost effectiveness of tofacitinib within its marketing authorisation for treating juvenile idiopathic arthritis.
 
Status In progress
Process STA 2018
ID number 2718

Provisional Schedule

Expected publication 20 October 2021

Project Team

Project lead Gavin Kenny

Email enquiries

Evidence Review Group / Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Consultees

Companies sponsors Pfizer (tofacitinib)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Action on Pain
  Arthritis Action
  Arthritis and Musculoskeletal Alliance
  Children’s Chronic Arthritis Association
  National Rheumatoid Arthritis Society
  Pain Concern
  Pain Relief Foundation
  Pain UK
  Psoriasis and Psoriatic Arthritis Alliance
  Psoriasis Association
  Psoriasis Help Organisation
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Versus Arthritis
Professional groups Royal College of Physicians

Commentators

Comparator companies AbbVie (adalimumab)
  Accord Healthcare UK (methotrexate) (confidentiality agreement not signed, not participating)
  Advanz Pharma (methotrexate) (confidentiality agreement not signed, not participating)
  Amgen UK (adalimumab)
  Biogen (adalimumab, etanercept, infliximab) (confidentiality agreement not signed, not participating)
  Bristol-Myers Squibb Pharmaceuticals (abatacept) (confidentiality agreement not signed, not participating)
  Celltrion Healthcare UK (infliximab) (confidentiality agreement not signed, not participating)
  Fresenius Kabi (adalimumab) (confidentiality agreement not signed, not participating)
  Hospira UK (methotrexate) (confidentiality agreement not signed, not participating)
  Medac GmbH (methotrexate) (confidentiality agreement not signed, not participating)
  Merck Sharpe & Dohme (infliximab) (confidentiality agreement not signed, not participating)
  Mylan UK (adalimumab) (confidentiality agreement not signed, not participating)
  Napp Pharmaceuticals (rituximab) (confidentiality agreement not signed, not participating)
  Nordic Pharma (methotrexate) (confidentiality agreement not signed, not participating)
  Orion Pharma UK (methotrexate) (confidentiality agreement not signed, not participating)
  Pfizer (etanercept, infliximab, methotrexate)
  Roche Products (rituximab, tocilizumab) (confidentiality agreement not signed, not participating)
  Rosemont Pharmaceuticals (methotrexate) (confidentiality agreement not signed, not participating)
  Sandoz (adalimumab, etanercept, infliximab, methotrexate, rituximab) (confidentiality agreement not signed, not participating)
  Swedish Orphan Biovitrum (anakinra)
  Therakind (methotrexate) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
01 December 2020 Invitation to participate
01 December 2020 In progress
31 July 2020 - 28 August 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance